ClinicalTrials.gg
Enrolling by invitationNCT05462600Updated Apr 11, 2025

Distribution of Ventilation, Respiratory Drive and Gas Exchange: Measurements and Monitoring

An observational study in Pulmonary Disease, Respiratory System Abnormalities and OSA, sponsored by University of California, San Diego. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by University of California, San Diego · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 406 studies in Lung Diseases with a site in United States — 66 open to participants now, 95 under way, 15 of them phase 3. Lung Diseases · United States.

Planned enrollment
93rd of 110
40 · median 198
Started
2022
with 19 others
Observational
110 of 406
20 open now
Primary completion
2026-12
later than 20 of 91 live
Registered
328th of 406
by date

Among the 406 studies in Lung Diseases with a site in United States, this one is the 93rd largest by planned enrollment of the 110 observational ones that give a count, is one of 20 that started in 2022, is one of 110 observational ones, reaches primary completion later than 20 of the 91 other live ones, and was the 328th registered.

Lung Diseases

1,159 studies on the registry are indexed under Lung Diseases; 181 are open to participants now.

Browse Lung Diseases studies →

Open to participants now

66 of the 406 studies in Lung Diseases with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 138 Lung Diseases studies recruiting now, 75 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 15 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 406 studies in Lung Diseases with a site in United States, or all of them as a file.
02

Study summary

Respiratory physiology involves a complex interplay of elements including control of breathing, respiratory drive, pulmonary mechanics, distribution of ventilation and gas exchange. Body position may also play an important role in respiratory mechanics. While effective methods exist for measuring these variables, they are typically measured in isolation rather than in combination. In pulmonary disease, decreasing mechanical stress and strain and optimizing transpulmonary pressure or the distending pressure across the lung, minimizing overdistention and collapse are central to clinical management. Obesity has a significant impact on pulmonary mechanics and is a risk factor for obstructive sleep apnea (OSA). However, our understanding of these elements is limited even in the general population. The investigators plan to use various validated methods to assess control of breathing, respiratory drive, distribution of ventilation and gas exchange to obtain a better understanding of underlying physiologic signatures in patients with and without obesity and the role of posture/position, with a secondary analysis comparing participants with and without obstructive sleep apnea.

03

Conditions studied

  • Pulmonary Disease
  • Respiratory System Abnormalities
  • OSA
  • Respiratory Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Investigators will enroll 20 subjects with BMI 18.5-24.9 and 20 subjects with BMI 25 or more. The detailed inclusion criteria for subjects are listed below.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Non-smokers

Exclusion criteria

Exclusion Criteria:

  • \<18 years old
  • Significant history of pulmonary disease
  • Chest wall, anatomical, physical abnormalities, skin integrity issues precluding placement of electrode belt in direct contact with skin
  • Skin integrity issues precluding placement of nose clips, or transcutaneous carbon dioxide monitoring
  • Inability to form a seal around a mouthpiece
  • Known esophageal strictures, webs, or varices (if esophageal manometry to be included)
  • Known count \< 100,000 (if esophageal manometry to be included)
  • On therapeutic anticoagulation (if esophageal manometry to be included)
  • Known multidrug resistant (MDR) pulmonary infection
  • Non-English language speakers
  • Chronic hypoxemic respiratory failure
  • Confirmed or suspected intracranial bleed, stroke, edema
  • Active implants (i.e. implantable electronic devices such as pacemakers, cardioverter defibrillators or neurostimulators) or if device compatibility is in doubt
  • Pregnant or lactating patients as safety and efficacy for use of EIT in such cases has not been verified
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • BMI>24.9 kg/m2

    Other: Position change

  • BMI 18-24.9 kg/m2

    Other: Position change

Interventions

  • OtherPosition change

    Distribution of ventilation, respiratory drive, pulmonary mechanics and gas exchange will be measured in 3 unique positions: prone, head of bed (HOB) flat (i.e. 0 degrees) and HOB elevated (i.e. 30 degrees).

06

What researchers measure

Primary outcomes

  1. Distribution of ventilation

    Change in regional ventilation distribution (ventral/dorsal) measured through electrical impedance tomography (EIT)

    Time frame: 3 hours

  2. Respiratory drive

    Respiratory drive differences will be measured by mean desaturation (change from baseline percent oxygen saturation) following breath-hold maneuvers

    Time frame: 3 hours

  3. Respiratory drive

    Respiratory drive differences will be assessed by the duration of maximal breath-hold (seconds)

    Time frame: 3 hours

  4. Respiratory drive

    Respiratory drive will also be assessed by measurement of occlusion pressure (cm H2O) at 100 ms (P0.1) after the initiation of an inspiratory effort against a closed circuit.

    Time frame: 3 hours

Secondary outcomes

  1. Pulmonary mechanics

    Pulmonary mechanics will be measured by transpulmonary pressure (cmH2O)obtained from esophageal manometry (transpulmonary pressure= airway pressure- esophageal pressure)

    Time frame: 3 hours

  2. Dead space fraction

    Dead space fraction will be calculated by partial pressure arterial/transcutaneous CO2 (PCO2) minus partial pressure of CO2 in mixed expired gas divided by the partial pressure of arterial/transcutaneous CO2

    Time frame: 3 hours

  3. Ventilatory ratio

    Ventilatory ratio will be calculated as measured minute ventilation multiplied by the measured partial pressure of PCO2 divided (transcutaneous) by the predicted minute ventilation based on ideal body weight multiplied by the ideal PaCO2

    Time frame: 3 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.

Of 131 non-industry observational studies under Lung Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 53 months is above that.

Counting every sponsor, half of 153 studies reached it within 36 months; a quarter within 15 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 18, 2022
StartActual
Jul 19, 2022
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05462600
Responsible party
Alex Pearce (Principal Investigator, University of California, San Diego) — Principal investigator
First posted
Jul 18, 2022
Start date
Jul 19, 2022
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 11, 2025

Study contacts

Alex Pearce
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion